Jan Joseph Melenhorst

28PUBLICATIONS
130CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Oct 10, 2025
Fine tuning towards the next generation of engineered T cells.

Tham T Nguyen, Patrick Ho, Sarah Staudt

|Sep 05, 2025
MCL1 may not mediate chemoresistance.

Kylin A Emhoff, Kunho Chung, Dongmei Zhang

|Feb 13, 2025
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness.

Beatriz C Oliveira, Saaurav Bari, J Joseph Melenhorst

|Jan 20, 2025
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.

Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall

|Nov 13, 2024
TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function.

Alexander J Dimitri, Amy E Baxter, Gregory M Chen

|Sep 25, 2024
The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer.

Bing Feng, Zhiliang Bai, Xiaolei Zhou

Pageof 5

Frequent Collaborators

9 joint publications

Carl H June

8 joint publications

Bruce L Levine

4 joint publications

Joseph A Fraietta

4 joint publications

Stephan A Grupp